Rectum – V9: 2027+
| Primary Site | Histology | Year of Diagnosis |
|---|---|---|
| C209 | 8000-8149, 8154, 8160-8231, 8243-8248, 8250-8682, 8690-8700, 8720-8790, 8940-8960, 8965-8983, 9000, 9050-9111, 9270, 9300-9312, 9340-9363, 9380-9539, 9541 | 2027-9998, 9999, <BLANK> |
Notes
**See table above for primary sites and histologies for this schema** C209: Rectum, NOS **Note 1:** **Sources used in the development of this schema** * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 20 *Colon and Rectum*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. Rectum, from the AJCC Cancer Staging System Version 9 (2026). Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** **Other EOD Schemas with Rectum sites** * **GIST**: 8935-8936 * **Kaposi Sarcoma**: 9140 * **Mycosis Fungoides**: 9700-9701 * **NET Colon and Rectum**: 8150-8153, 8155-8156, 8158, 8240-8242, 8249, 8683 * **Soft Tissue Abdomen and Thoracic**: 8710-8714, 8800-8803, 8810-8921, 8932-8934, 8963-8964, 8990, 8992, 9010-9016, 9030-9043, 9045, 9120-9138, 9141-9230, 9240-9262, 9271-9290, 9320-9330, 9364-9373, 9540, 9542-9580, 9582 * **Soft Tissue Rare**: 8804-8806, 8930-8931, 8991, 9020, 9044, 9231, 9581Data Items
| Name | Default Value | Used in Derivation | NAACCR Item | Required By | Metadata |
|---|---|---|---|---|---|
| Year of Diagnosis | Yes |
NAACCR #390
dateOfDiagnosis |
None | ||
| Primary Site | Yes |
NAACCR #400
primarySite |
None | ||
| Histology | Yes |
NAACCR #522
histologicTypeIcdO3 |
None | ||
| Behavior | No |
NAACCR #523
behaviorCodeIcdO3 |
None | ||
| Type of Reporting Source | No |
NAACCR #500
typeOfReportingSource |
None | ||
| Tumor Size Clinical | No |
NAACCR #752
tumorSizeClinical |
None | ||
| Tumor Size Pathological | No |
NAACCR #754
tumorSizePathologic |
None | ||
| Tumor Size Summary | 999 | No |
NAACCR #756
tumorSizeSummary |
None | |
| Regional Nodes Positive | 99 | No |
NAACCR #820
regionalNodesPositive |
None | |
| Regional Nodes Examined | 99 | No |
NAACCR #830
regionalNodesExamined |
None | |
| EOD Primary Tumor | 999 | Yes |
NAACCR #772
eodPrimaryTumor |
None | |
| EOD Regional Nodes | 999 | Yes |
NAACCR #774
eodRegionalNodes |
None | |
| EOD Mets | 00 | Yes |
NAACCR #776
eodMets |
None | |
| SS2018 | No |
NAACCR #764
summaryStage2018 |
None | ||
| Grade Clinical | 9 | Yes |
NAACCR #3843
gradeClinical |
All | SSDI |
| Grade Pathological | 9 | Yes |
NAACCR #3844
gradePathological |
All | SSDI |
| Grade Post Therapy Clin (yc) | No |
NAACCR #1068
gradePostTherapyClin |
COC NPCR SEER |
SSDI | |
| Grade Post Therapy Path (yp) | No |
NAACCR #3845
gradePostTherapy |
CCCR/Canada COC NPCR SEER |
SSDI | |
| CEA PreTX Lab Value | XXXX.8 | No |
NAACCR #3820
ceaPretreatmentLabValue |
COC SEER |
SSDI |
| CEA PreTX Interpretation | 8 | No |
NAACCR #3819
ceaPretreatmentInterpretation |
CCCR/Canada COC SEER |
SSDI |
| Tumor Deposits | X8 | No |
NAACCR #3934
tumorDeposits |
COC SEER 2018–2023 SEER (RC) 2024– |
SSDI |
| Perineural Invasion | 8 | No |
NAACCR #3909
perineuralInvasion |
COC SEER |
SSDI |
| Circumferential Resection Margin | XX.8 | No |
NAACCR #3823
circumferentialResectionMargin |
CCCR/Canada COC SEER |
SSDI |
| KRAS | 8 | No |
NAACCR #3866
kras |
COC SEER |
SSDI |
| Microsatellite Instability (MSI) | 8 | No |
NAACCR #3890
microsatelliteInstability |
CCCR/Canada COC NPCR SEER |
SSDI |
| BRAF Mutational Analysis | 8 | No |
NAACCR #3940
brafMutationalAnalysis |
COC 2021– SEER 2021– |
SSDI 2021– |
| NRAS Mutational Analysis | 8 | No |
NAACCR #3941
nrasMutationalAnalysis |
COC 2021– SEER 2021– |
SSDI 2021– |
| Macroscopic Evaluation of the Mesorectum | No |
NAACCR #3950
macroscopicEvalOfTheMesorectum |
COC 2022– SEER (RC) 2022– |
SSDI 2022– | |
| Neoadjuvant Therapy | 9 | No |
NAACCR #1632
neoadjuvantTherapy |
SEER 2021– | SSDI 2021– |
| Neoadjuvant Therapy – Clinical Response | 99 | No |
NAACCR #1633
neoadjuvTherapyClinicalResponse |
SEER 2021– | SSDI 2021– |
| Neoadjuvant Therapy – Treatment Effect | 9 | No |
NAACCR #1634
neoadjuvTherapyTreatmentEffect |
COC 2027– SEER 2021– |
SSDI 2021– |
| Rectal Tumor Location | 9 | No |
NAACCR #3965
rectalTumorLocation |
COC 2027– SEER 2027– |
SSDI 2027– |
Initial Context
Outputs
| Name | Default Value | Description | NAACCR Item | Metadata |
|---|---|---|---|---|
| Schema ID | 09202 |
NAACCR #3800
schemaId |
None | |
| Derived Version | {{ctx_alg_version}} | None | None | |
| Derived Summary Stage 2018 | 9 |
NAACCR #762
derivedSummaryStage2018 |
None | |
| Derived Summary Grade 2018 | <BLANK> |
NAACCR #1975
derivedSummaryGrade2018 |
None |